STOK - CIK 0001623526
The table below shows Stoke Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.66M | $83.39M | $101.47M | $274.82M | $150.02M | $193.48M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $4.45M | $9.25M | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $366.68M |
| $272.44M |
| $269.97M |
| $375.74M |
| $253.61M |
| $296.99M |
| Property, plant & equipment | $3.40M | $3.08M | $3.34M | $3.61M | $4.33M | $4.77M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $443.28M | $360.26M | $384.51M | $406.89M | $293.32M | $307.76M |
| Accounts payable | $6.84M | $5.87M | $4.31M | $2.19M | $2.48M | $3.94M |
| Total current liabilities | $40.81M | $41.73M | $38.68M | $44.69M | $49.87M | $44.50M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $48.40M | $52.16M | $49.56M | $56.81M | $61.21M | $65.05M |
| Retained earnings | -$547.72M | -$439.78M | -$401.43M | -$377.95M | -$480.35M | -$453.92M |
| Total equity | $394.88M | $308.11M | $334.94M | $350.07M | $232.11M | $242.71M |